Shanghai MicroPort Endovascular MedTech Beheer

Beheer criteriumcontroles 2/4

Momenteel beschikken wij niet over voldoende informatie over de CEO.

Belangrijke informatie

Qing Zhu

Algemeen directeur

CN¥3.9m

Totale compensatie

Percentage CEO-salaris	n/a
Dienstverband CEO	6.3yrs
Eigendom CEO	n/a
Management gemiddelde ambtstermijn	3.7yrs
Gemiddelde ambtstermijn bestuur	1.8yrs

Recente managementupdates

Recent updates

CEO

Qing Zhu (43 yo)

6.3yrs

Tenure

CN¥3,943,900

Compensatie

Mr. Qing Zhu is GM & Director of Shanghai MicroPort Endovascular MedTech Co., Ltd. He was Deputy General Manager of Shanghai MicroPort Endovascular MedTech Co., Ltd.

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Qing Zhu	GM & Director	no data	CN¥3.94m	geen gegevens
Chun Fang Li	Accounting Supervisor & CFO	3.1yrs	CN¥1.21m	geen gegevens
Genyong Qiu	Deputy GM & Secretary of the Board of Directors	2.6yrs	CN¥1.89m	geen gegevens
Zhenyu Yuan	Deputy GM & Core Technical Personnel	5.7yrs	CN¥2.13m	geen gegevens
Lantao Guo	Deputy GM & Core Technical Personnel	4.3yrs	CN¥1.79m	geen gegevens
Ke Chen	Senior Director	no data	CN¥1.68m	geen gegevens
Hongjie Lu	Core Technical Staff	no data	CN¥488.00k	geen gegevens
Liwen Wang	Core Technical Staff	no data	CN¥687.10k	geen gegevens

3.7yrs

Gemiddelde duur

44yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van 688016 wordt beschouwd als ervaren (gemiddelde ambtstermijn 3.7 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Qing Zhu	GM & Director	6.3yrs	CN¥3.94m	geen gegevens
Jonathan H. Chen	Chairman	less than a year	geen gegevens	geen gegevens
Linlin Cai	Employee Representative Supervisor	6.3yrs	geen gegevens	geen gegevens
Xiaojie Ye	Independent Director	2.7yrs	geen gegevens	geen gegevens
Min Liang	Chairman of the Supervisory Board	less than a year	geen gegevens	geen gegevens
Chao Guo	Supervisor	less than a year	geen gegevens	geen gegevens

1.8yrs

Gemiddelde duur

40.5yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van 688016 wordt niet als ervaren beschouwd (gemiddelde ambtstermijn 1.8 jaar), wat duidt op een nieuw bestuur.

Shanghai MicroPort Endovascular MedTech Beheer

Beheer criteriumcontroles 2/4

Belangrijke informatie

Recente managementupdates

Less than half of directors are independent

Shanghai MicroPort Endovascular MedTech Co., Ltd., Annual General Meeting, Apr 18, 2024

Insufficient new directors

Less than half of directors are independent

Insufficient new directors

Recent updates

Third quarter 2024 earnings released: EPS: CN¥1.22 (vs CN¥1.02 in 3Q 2023)

Investor sentiment deteriorates as stock falls 20%

Now 24% undervalued

Shanghai MicroPort Endovascular MedTech Co., Ltd. to Report Q3, 2024 Results on Oct 30, 2024

Investor sentiment improves as stock rises 19%

Second quarter 2024 earnings released: EPS: CN¥1.77 (vs CN¥1.44 in 2Q 2023)

Investor sentiment deteriorates as stock falls 16%

Now 22% undervalued after recent price drop

Less than half of directors are independent

Shanghai MicroPort Endovascular MedTech Co., Ltd. (SHSE:688016) announces an Equity Buyback for CNY 100 million worth of its shares.

Shanghai MicroPort Endovascular MedTech Co., Ltd. to Report First Half, 2024 Results on Aug 27, 2024

First quarter 2024 earnings released: EPS: CN¥2.23 (vs CN¥1.73 in 1Q 2023)

Now 20% overvalued after recent price rise

Shanghai MicroPort Endovascular MedTech Co., Ltd. to Report Q1, 2024 Results on Apr 26, 2024

Shanghai MicroPort Endovascular MedTech Co., Ltd., Annual General Meeting, Apr 18, 2024

Now 24% overvalued

Full year 2023 earnings released: EPS: CN¥6.81 (vs CN¥4.96 in FY 2022)

Full year 2023 earnings released: EPS: CN¥6.81 (vs CN¥4.96 in FY 2022)

Investor sentiment improves as stock rises 18%

Now 20% overvalued

Shanghai MicroPort Endovascular MedTech (Group) Co., Ltd. Provides Earnings Guidance for the Year Ended 31 December 2023

Shanghai MicroPort Endovascular MedTech Co., Ltd. to Report Fiscal Year 2023 Results on Mar 28, 2024

New minor risk - Shareholder dilution

Third quarter 2023 earnings released: EPS: CN¥1.52 (vs CN¥1.19 in 3Q 2022)

Second quarter 2023 earnings released: EPS: CN¥2.16 (vs CN¥1.27 in 2Q 2022)

Full year 2022 earnings released: EPS: CN¥4.96 (vs CN¥4.39 in FY 2021)

Shanghai MicroPort Endovascular MedTech Co., Ltd. Provides Earnings Guidance for the Year Ended 31 December 2022

Insufficient new directors

Third quarter 2022 earnings released: EPS: CN¥1.19 (vs CN¥0.90 in 3Q 2021)

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Second quarter 2022 earnings released: EPS: CN¥1.27 (vs CN¥1.16 in 2Q 2021)

Investor sentiment deteriorated over the past week

Shanghai MicroPort Endovascular MedTech Co., Ltd. announced that it expects to receive CNY 2.5468393 billion in funding

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

First quarter 2022 earnings released: EPS: CN¥1.72 (vs CN¥1.41 in 1Q 2021)

Less than half of directors are independent

Full year 2021 earnings released: EPS: CN¥4.39 (vs CN¥2.98 in FY 2020)

Investor sentiment improved over the past week

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

Shanghai MicroPort Endovascular MedTech (Group) Co., Ltd. Provides Earnings Guidance for the Year Ended December 31, 2021

Insufficient new directors

CEO

Tenure

Compensatie

Leiderschapsteam

Gemiddelde duur

Gemiddelde leeftijd

Bestuursleden

Gemiddelde duur

Gemiddelde leeftijd